The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers
Abstract
Over 1000 different mutants of the tumor suppressor protein p53 with one amino acid change in the core domain have been reported in human cancers. In mouse knock-in models, two frequent mutants displayed loss of wild-type (wt) p53 function, inhibition of wt p53 and wt p53-independent gain of function. The remaining mutants have been systematically characterized for loss of wt p53 function, but not other phenotypes. We report the concomitant assessment of loss of function and interference with wt p53 using URA3-based p53 yeast and confirmatory mammalian assays. We studied 76 mutants representing 54% of over 15 000 reported missense core domain mutations. The majority showed the expected complete loss of wt p53 function and dominant p53 inhibition. A few infrequent p53 mutants had wt p53-like activity. Remarkably, one-third showed no interference with wt p53 despite loss of wt p53 function at 37 degrees C. Half of this group consisted of temperature-sensitive p53 mutants, but the other half was surprisingly made up of mutants with complete loss of wt p53 function. Our findings illustrate the diverse behavior of p53 mutants and mechanisms of malignant transformation by p53 mutants. The identification of full-length p53 mutants without dominant inhibition of wt p53 highlights the importance of determining the status of the wt p53 allele in human cancers, in particular in the context of clinical studies. In the case of p53 mutants with no or weak dominant p53 inhibition, presence of the wt allele may indicate a good prognosis cancer, whereas loss of heterozygosity may spell an aggressive, therapy-resistant cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in important arginine residues located on the p53-DNA-binding surface facilitate the loss of transcriptional activity and sequence-specific DNA binding.28,145”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“The 393 amino acid protein has an N-terminal transactivation domain, a core domain that recognizes p53 DNA binding sites (DBS), and a C-terminal tetramerization domain (1, 2 ).”
BackgroundCrystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202033 · Cited by 200
The UMD TP53 database and website: update and revisions
Hamroun, D., Kato, S., Ishioka, C., Claustres, M., Béroud, C., & Soussi, T. (2006) · Human Mutation · doi:10.1002/humu.20269 · Cited by 140
Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library
Shiraishi, K., Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Sakayori, M., Ishida, T., Takeda, M., Kanamaru, R., Ohuchi, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310815200 · Cited by 96
Research works printed but not linked: 49
- Prives, 1999, The p53 pathway, J. Pathol., 187, 112, 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 · doi:10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3
- Corcoran, 2004, The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest, Cancer. Biol. Ther., 3, 721, 10.4161/cbt.3.8.1068 · DOI
- Ho, 2003, Transcriptional repression mediated by the p53 tumour suppressor, Cell. Death Differ., 10, 404, 10.1038/sj.cdd.4401191 · DOI · Paper page
- Erster, 2005, Stress-induced p53 runs a transcription-independent death program, Biochem. Biophys. Res. Commun., 331, 843, 10.1016/j.bbrc.2005.03.187 · DOI
- Bullock, 2001, Rescuing the function of mutant p53, Nat. Rev. Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
- Sigal, 2000, Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome, Cancer Res., 60, 6788
- Blagosklonny, 2000, p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect, FASEB J., 14, 1901, 10.1096/fj.99-1078rev · DOI · Paper page
- Greenblatt, 1994, Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res., 54, 4855
- Ko, 1996, p53: puzzle and paradigm, Genes Dev., 10, 1054, 10.1101/gad.10.9.1054 · DOI · Paper page
- Campomenosi, 2001, p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements, Oncogene, 20, 3573, 10.1038/sj.onc.1204468 · DOI
- Di Como, 1998, Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay, Oncogene, 16, 2527, 10.1038/sj.onc.1202041 · DOI · Paper page
- Flaman, 1998, Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast, Oncogene, 16, 1369, 10.1038/sj.onc.1201889 · DOI
- Friedlander, 1996, Regulation of mutant p53 temperature-sensitive DNA binding, J. Biol. Chem., 271, 25468, 10.1074/jbc.271.41.25468 · DOI
- Ludwig, 1996, Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function, Mol. Cell. Biol., 16, 4952, 10.1128/MCB.16.9.4952 · DOI · Paper page
- Rowan, 1996, Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant, EMBO J, 15, 827, 10.1002/j.1460-2075.1996.tb00418.x · DOI · Paper page
- Milner, 1991, Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation, Cell, 65, 765, 10.1016/0092-8674(91)90384-B · DOI · Paper page
- Brachmann, 1996, Dominant-negative p53 mutations selected in yeast hit cancer hot spots, Proc. Natl Acad. Sci. USA, 93, 4091, 10.1073/pnas.93.9.4091 · DOI · Paper page
- Aurelio, 2000, p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines, Mol. Cell. Biol., 20, 770, 10.1128/MCB.20.3.770-778.2000 · DOI
- de Vries, 2002, Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function, Proc. Natl Acad. Sci. USA, 99, 2948, 10.1073/pnas.052713099 · DOI · Paper page
- Scharer, 1992, Mammalian p53 can function as a transcription factor in yeast, Nucleic Acids Res., 20, 1539, 10.1093/nar/20.7.1539 · DOI · Paper page
- Ishioka, 1993, Screening patients for heterozygous p53 mutations using a functional assay in yeast, Nat. Genet., 5, 124, 10.1038/ng1093-124 · DOI · Paper page
- Kato, 2003, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis, Proc. Natl Acad. Sci. USA, 100, 8424, 10.1073/pnas.1431692100 · DOI · Paper page
- Resnick, 2003, Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity, Proc. Natl Acad. Sci. USA, 100, 9934, 10.1073/pnas.1633803100 · DOI · Paper page
- Robert, 2000, High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis, Carcinogenesis, 21, 563, 10.1093/carcin/21.4.563 · DOI
- Inga, 1997, Simple identification of dominant p53 mutants by a yeast functional assay, Carcinogenesis, 18, 2019, 10.1093/carcin/18.10.2019 · DOI
- Marutani, 1999, Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme, Cancer Res., 59, 4765
- Monti, 2002, Tumour p53 mutations exhibit promoter selective dominance over wild type p53, Oncogene, 21, 1641, 10.1038/sj.onc.1205250 · DOI
- Brachmann, 1998, Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations, EMBO J., 17, 1847, 10.1093/emboj/17.7.1847 · DOI · Paper page
- Baroni, 2004, A global suppressor motif for p53 cancer mutants, Proc. Natl Acad. Sci. USA, 101, 4930, 10.1073/pnas.0401162101 · DOI
- Vidal, 1996, Reverse two-hybrid and one-hybrid systems to detect dissociation of protein–protein and DNA–protein interactions, Proc. Natl Acad. Sci. USA, 93, 10315, 10.1073/pnas.93.19.10315 · DOI · Paper page
- Qian, 2002, Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites, Oncogene, 21, 7901, 10.1038/sj.onc.1205974 · DOI
- Kern, 1992, Oncogenic forms of p53 inhibit p53-regulated gene expression, Science, 256, 827, 10.1126/science.1589764 · DOI · Paper page
- Baker, 1990, Suppression of human colorectal carcinoma cell growth by wild-type p53, Science, 249, 912, 10.1126/science.2144057 · DOI · Paper page
- Dearth, 2003, Posttranscriptional and posttranslational regulation of C/EBP delta in G0 growth-arrested mammary epithelial cells, J. Biol. Chem., 278, 11246, 10.1074/jbc.M207930200 · DOI
- Bougeard, 2006, Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome, J. Med. Genet., 43, 531, 10.1136/jmg.2005.037952 · DOI · Paper page
- Soussi, 2005, Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations, Hum. Mutat., 25, 6, 10.1002/humu.20114 · DOI
- Olivier, 2003, Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype, Cancer Res., 63, 6643
- Varley, 2003, Germline TP53 mutations and Li-Fraumeni syndrome, Hum. Mutat., 21, 313, 10.1002/humu.10185 · DOI · Paper page
- Trkova, 2003, A Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumors, Cancer Genet. Cytogenet., 145, 60, 10.1016/S0165-4608(03)00031-1 · DOI
- Varley, 1997, A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene, Oncogene, 14, 865, 10.1038/sj.onc.1201041 · DOI
- Huang, 2000, High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal squamous cell carcinomas from a high incidence area in northern China, Carcinogenesis, 21, 2019, 10.1093/carcin/21.11.2019 · DOI
- Guan, 2003, Evidence for another tumor suppressor gene at 17p13.3 distal to TP53 in hepatocellular carcinoma, Cancer Genet. Cytogenet., 140, 45, 10.1016/S0165-4608(02)00654-4 · DOI
- Konishi, 1998, Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers, Oncogene, 17, 2095, 10.1038/sj.onc.1202128 · doi:10.1038/sj.onc.1202128
- Soussi, 2003, p53 mutations and resistance to chemotherapy: a stab in the back for p73, Cancer Cell, 3, 303, 10.1016/S1535-6108(03)00081-3 · DOI
- Moll, 2004, p63 and p73: roles in development and tumor formation, Mol. Cancer Res., 2, 371, 10.1158/1541-7786.371.2.7 · DOI · Paper page
- Marin, 2000, A common polymorphism acts as an intragenic modifier of mutant p53 behaviour, Nat. Genet., 25, 47, 10.1038/75586 · DOI · Paper page
- Bergamaschi, 2003, p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis, Cancer Cell, 3, 387, 10.1016/S1535-6108(03)00079-5 · DOI · Paper page
- Russo, 2005, The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment, J. Clin. Oncol., 23, 7518, 10.1200/JCO.2005.00.471 · DOI · Paper page
- Olivier, 2006, The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer, Clin. Cancer Res., 12, 1157, 10.1158/1078-0432.CCR-05-1029 · DOI · Paper page
Cited by
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
“Since then, data has been produced on more than 200 mutants and it appears that DNE is promoter- and cell-typedependent [Dearth et al., 2007].”
BackgroundWhen mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661
Metadata
- Authors
- Dearth, L. R., Qian, H., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-02
- Volume
- 28
- Issue
- 2
- Pages
- 289-298
- ISSN
- 1460-2180
- 0143-3334
- Cited by
- 120
- References
- 11
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.